Major Topics:
1. Tumor immunology and immunotherapy
2. Cancer genomics and targeted therapy
3. Cancer stem cells
4. Cancer pathways
5. Tumor metastasis
6. New technologies and large-scale cancer biology
Keynote Speakers:
James Allison, The University of Texas MD Anderson Cancer Center, USA
Abstract title: Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities, and prospects for Cures
Confirmed Speakers:
Hiroyuki Aburatani, University of Tokyo, Japan
Abstract title: Genomic classification of gastric cancer for treatment selection
Priscilla Brastianos, Dana-Farber/Harvard Cancer Center, USA
Frederic De Sauvage, Genentech, Inc., USA
Abstract title: Targeting intestinal stem cells in cancer.
Chen Dong, Tsinghua University, CHINA
Abstract title: Understanding and modulating tumor microenvironment
Yang-Xin Fu, UT Southwestern Medical Center, USA
Abstract title: Targeted therapies that bridge innate and adaptive immunity
Thomas Gajewski, University of Chicago, Medical School, USA
Abstract title: Tumor and host pathways regulating anti-tumor immunity and immunotherapy efficacy
Jerome Galon, INSERM U872, Cordeliers Research Center, FRANCE
Philip Greenberg, Fred Hutchinson Cancer Research Center, USA
Abstract title: Engineering T cells to eradicate tumors in the age of synthetic biology
Hongbin Ji, Institute of Biochemistry & Cell Biology, SIBS, CAS, CHINA
Abstract title: Phenotypic Transition Contributes to Small Cell Lung Carcinoma Metastasis
Kazuhiro Kakimi, The University of Tokyo, JAPAN
Abstract title: An immunogram for the cancer-immunity cycle: towards personalized immunotherapy
Raghu Kalluri, MD Anderson Cancer Center, USA
Michael Karin, University of California, San Diego, USA
Abstract title: Immune control of liver tumorigenesis – basic concepts and implications for treatment
Yutaka Kawakami, Keio University School of Medicine, JAPAN
Abstract title: Heterogeneity in the tumor-immune-microenvironments in human cancers and its personalized modulation
Vijay Kuchroo, Harvard Medical School, USA
Abstract title: IL-27 drives a transcriptional program that sets the stage for T cell dysfunction
Xiaole Shirley Liu, Dana-Farber Cancer Institute, Harvard University, USA
Abstract title: Inference of gene signatures associated with response and resistance to targeted and immunotherapies
Flavius Martin, Amgen, USA
Tak Mak, Ontario Cancer Institute, CANADA
Abstract title: Beyond Targeting Oncogenes: Emerging Anti-Cancer Strategies
Satoru Miyano, University of Tokyo, JAPAN
Abstract title: Supercomputer challenges for cancer genomics and TCR data analysis
Hidewaki Nakagawa, RIKEN Center for Integrative Medical Science, JAPAN
Abstract title: Cancer Whole Genome Sequencing for Precision Oncology and Cancer Immunology
Seishi Ogawa, Kyoto University, Graduate School of Medicine, JAPAN
Wenjun Ouyang, Amgen, USA
Abstract title: Engage and enhance the functions of T cells in cancer immunotherapies
John EJ Rasko, University of Sydney, AUSTRALIA
Abstract title: Manufacturing, regulatory and logistical challenges in clinical cell & gene therapies
Somasekar Seshagiri, Genentech Inc, USA
Abstract title: Targetable activating Her2 transmembrane domain mutations in human cancers
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, USA
Abstract title: From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy
Arlene Sharpe, Harvard Medical School, USA
Abstract title: Biology of PD-1 Checkpoint Blockade
Tatsuhiro Shibata, National Cancer Center Research Institute, JAPAN
Abstract title: Intersection of genome and immunological microenvironments in human hepatobiliaty cancer
Ramesh Shivdasani, Harvard Medical School Dana-Farber Cancer Institute, USA
Abstract title: Intestinal stem cell plasticity and its chromatin basis
Patrick Tan, Duke-NUS Medical School, SINGAPORE
Abstract title: Genomic and Epigenomic Profiles of Asian Endemic Cancers
Hong Wu, Peking University, CHINA
Abstract title: T-ALL leukemia stem cell fate is epigenetically controlled by the master regulator PU.1
Xiaoliang Sunney Xie, Harvard University, USA
Chengcheng (Alec) Zhang, UT Southwestern Medical Center, USA
Abstract title: ITIM receptors: immune checkpoint proteins and tumor supporting factors
Pan Zheng, Children's National Health System, USA
Abstract title: Searching for Better and Safer Anti-CTLA4 Antibody for Cancer Immunotherapy
Xingxing Zang, Albert Einstein College of Medicine, USA
Abstract title: New immune checkpoint pathways: HHLA2 and its receptors including TMIGD2
Zemin Zhang, Peking University, CHINA
Abstract title: Single cell analysis of tumor microenvironment reveals distinct patterns of clonal expansion and functional states of immune cells
We encourage abstracts to contain new and unpublished materials. The abstracts must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentation will be made by the organizers. Status (fellow's talk/poster) of abstracts will be posted on our web site as soon as decisions have been made by the organizers.
Fellowship:
We are eager to have as many young people as possible attend since they are likely to benefit most from this meeting. A certain number of presentations by graduate students and postdocs in this conference will be selected as fellowship (USD $100-$500) awards. For more details, please visit http://www.csh-asia.org/stipends.html
We look forward to seeing you at Suzhou in September, 2017.
Sponsored by:
